E2F6 Transcription Factor

An E2F transcription factor that represses GENETIC TRANSCRIPTION required for CELL CYCLE entry and DNA synthesis. E2F6 recruits chromatin remodeling factors directly to target gene promoters and lacks the transactivation domain responsible for binding to the retinoblastoma family of tumor suppressors.

Also Known As:

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ding, Feng: 1 article (01/2020)
2.	Zhao, Hui: 1 article (01/2020)
3.	Zheng, Guanghong: 1 article (01/2020)
4.	Chan, Michael W Y: 1 article (03/2019)
5.	Chang, Chia-Bin: 1 article (03/2019)
6.	Chen, Gary C W: 1 article (03/2019)
7.	Chen, Yin-Chen: 1 article (03/2019)
8.	Cheng, Alfred S L: 1 article (03/2019)
9.	Cheng, Frank H C: 1 article (03/2019)
10.	Chou, Jian-Liang: 1 article (03/2019)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2020 - "Taken together, we demonstrated lncRNA TMPO-AS1 could potentially promote LCN2 transcriptional activity by binding to transcription factor E2F6, and thus, stimulated the progression of ovarian cancer. " 03/01/2019 - "To decipher a mechanism for this, we previously generated a mathematical model of how estrogen-mediated upregulation of the transcription factor, E2F6, upregulates the ovarian cancer stem/initiating cell marker, c-Kit, by epigenetic silencing the tumor suppressor miR-193a, and a competing endogenous (ceRNA) mechanism. "
2.	Neoplasms (Cancer) 03/01/2019 - "To decipher a mechanism for this, we previously generated a mathematical model of how estrogen-mediated upregulation of the transcription factor, E2F6, upregulates the ovarian cancer stem/initiating cell marker, c-Kit, by epigenetic silencing the tumor suppressor miR-193a, and a competing endogenous (ceRNA) mechanism. "

Related Drugs and Biologics

1.	Long Noncoding RNA
2.	Estrogens (Estrogen)
3.	Competitive Endogenous RNA